[quoteThe rapid progression of metastatic sarcomas demonstrates the aggressive nature of these malignancies, and maintenance therapy with R will provide a new option for pts with this life-threatening disease. ][/quote]
Thats the key takeaway here. Despite insufficient OS data, its clear that Merck intends to go to market with this drug. I assume OS will be closer to Dews figure when they report final data. Right now, its almost two and one half months, which isnt bad.
To be honest, I kinda wish Ridaforolimus would just go away..from a shareholders perspective. Underwhelming, at best.
